(0.61%) 5 077.50 points
(0.39%) 38 216 points
(0.81%) 17 580 points
(0.91%) $79.72
(2.28%) $1.976
(0.37%) $2 319.60
(-0.03%) $26.74
(1.38%) $968.10
(0.06%) $0.934
(0.15%) $11.05
(0.01%) $0.799
(-1.27%) $92.07
Live Chart Being Loaded With Signals
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products...
Stats | |
---|---|
本日の出来高 | 156 000 |
平均出来高 | 1.18M |
時価総額 | 9.61B |
EPS | HKD0.180 ( 2023-09-30 ) |
Last Dividend | HKD0.219 ( 2023-07-07 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 7.14 |
ATR14 | HKD0.00400 (0.07%) |
ボリューム 相関
Shandong Xinhua 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Shandong Xinhua 相関 - 通貨/商品
Shandong Xinhua 財務諸表
Annual | 2023 |
収益: | HKD8.10B |
総利益: | HKD2.39B (29.52 %) |
EPS: | HKD0.740 |
FY | 2023 |
収益: | HKD8.10B |
総利益: | HKD2.39B (29.52 %) |
EPS: | HKD0.740 |
FY | 2022 |
収益: | HKD7.50B |
総利益: | HKD2.04B (27.15 %) |
EPS: | HKD0.620 |
FY | 2021 |
収益: | HKD6.56B |
総利益: | HKD1.77B (27.04 %) |
EPS: | HKD0.560 |
Financial Reports:
No articles found.
Shandong Xinhua Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.176 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.219 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0308 | 2000-05-10 |
Last Dividend | HKD0.219 | 2023-07-07 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | HKD1.419 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.66 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.80 | |
Div. Directional Score | 9.77 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
9869.HK | Ex Dividend Junior | 2023-09-19 | Insufficient data to determine frequency | 0 | 0.00% | |
2138.HK | Ex Dividend Junior | 2023-09-01 | Semi-Annually | 0 | 0.00% | |
1133.HK | Ex Dividend Junior | 2023-06-15 | Sporadic | 0 | 0.00% | |
0217.HK | Ex Dividend Junior | 2023-07-05 | Sporadic | 0 | 0.00% | |
3836.HK | Ex Dividend Junior | 2023-06-16 | Annually | 0 | 0.00% | |
1717.HK | Ex Dividend Junior | 2023-06-01 | Sporadic | 0 | 0.00% | |
0752.HK | Ex Dividend Knight | 2023-07-14 | Annually | 0 | 0.00% | |
2317.HK | Ex Dividend Junior | 2023-09-14 | Annually | 0 | 0.00% | |
1285.HK | Ex Dividend Knight | 2023-07-18 | Annually | 0 | 0.00% | |
0345.HK | Ex Dividend Knight | 2023-08-31 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0613 | 1.500 | 8.77 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0575 | 1.200 | 8.08 | 9.70 | [0 - 0.3] |
returnOnEquityTTM | 0.107 | 1.500 | 9.92 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.356 | -1.000 | 6.44 | -6.44 | [0 - 1] |
currentRatioTTM | 1.425 | 0.800 | 7.87 | 6.30 | [1 - 3] |
quickRatioTTM | 0.916 | 0.800 | 9.32 | 7.46 | [0.8 - 2.5] |
cashRatioTTM | 0.378 | 1.500 | 9.01 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.155 | -1.500 | 7.41 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 13.47 | 1.000 | 6.12 | 6.12 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.665 | 2.00 | 9.78 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.189 | 2.00 | 9.91 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.276 | -1.500 | 8.90 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.283 | 1.000 | 8.62 | 8.62 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0654 | 1.000 | -0.691 | -0.691 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.341 | 1.000 | 9.21 | 9.21 | [0.2 - 2] |
assetTurnoverTTM | 0.937 | 0.800 | 7.09 | 5.67 | [0.5 - 2] |
Total Score | 12.75 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 6.90 | 1.000 | 9.40 | 0 | [1 - 100] |
returnOnEquityTTM | 0.107 | 2.50 | 9.95 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.189 | 2.00 | 9.94 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.40 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.665 | 2.00 | 9.78 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.356 | 1.500 | 6.44 | -6.44 | [0 - 1] |
pegRatioTTM | 0.918 | 1.500 | 7.22 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0566 | 1.000 | -1.085 | 0 | [0.1 - 0.5] |
Total Score | 6.80 |
Shandong Xinhua
Shandong Xinhua Pharmaceutical Company Limited, through its subsidiaries, develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products. It operates through Chemical bulk drugs, Preparations, and Chemical intermediates and Others segments. The company offers active pharmaceutical ingredients, pharmaceutical preparations, and chemical products, such as antipyretic analgesics; drugs for cardiovascular and cerebrovascular diseases; anti-infectives; drugs for diseases related to the central nervous system; and other drugs under the Xinhua brand. It also provides prepared Chinese herbal medicine decoction, traditional Chinese medicines, chemical preparations, antibiotics, biochemical medicines, chemical bulk drugs, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc.; and chemical raw materials, such as dimethyl sulfate, isobutylbenzene, 1,8-diazabicyclo, undec-7-ene, and tetramethylguanidine. In addition, the company offers materials and intermediates, powders for injection and tablets; tablets, hard capsules, granules, and dry suspension; imports and exports goods and technologies; designs medical projects; and health products research and development activities. Further, it engages in the certification business; electrical equipment engineering; and installation and testing of chemical equipment and electrical equipment, as well as the sale of mechanical, hardware, and electrical equipment. Additionally, the company produces and sells high-end steroid system APIs and intermediates; and provides internet data, internet sells, and internet information services for pharmaceuticals and medical devices, etc. It operates in the People's Republic of China, the Americas, Europe, and internationally. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。